GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...
A recent example of content that inspired a positive response was the profiling of women in management within GSK, to mark International Women's Day which took place on 8th March. The theme of ...
Hosted on MSN12mon
Is the GSK share price too cheap to ignore?For these reasons, I would be buying GSK shares if I had the spare cash today. Investors who don’t own energy shares need to see this now. Because Mark Rogers — The Motley Fool UK’s Director ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback